Personalized cell therapies show more promise in solid tumors

Glioblastoma (histology slide). Credit: Wikipedia/CC BY-SA 3.0

Investigational “hunter” immune cells engineered to seek out and attack a deadly brain cancer known as glioblastoma (GBM) infiltrated patients’ tumors and triggered thousands of more T cells once inside, researchers from Penn Medicine reported in a late breaking abstract at the AACR Annual Meeting 2017 (Abstract LB-053). The findings are among the results from three studies being presented on chimeric antigen receptor (CAR) therapy with T cells and a newer approach known as CARMA, which successfully pitted engineered

... read more at: